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Summary 
To define the role of interleukin (IL) 6 in Candida albicans infection, IL-6-deficient mice were 
assessed  for susceptibility to systemic or gastrointestinal infection,  as well as for parameters of 
elicited T  helper cell  (Th)  immunity.  IL-6-deficient mice were more susceptible than wild- 
type mice to either type of infection caused by virulent  C.  albicans. In response to systemic 
challenge with a live vaccine strain of the yeast, IL-6-deficient mice failed to mount Thl-asso- 
ciated protective immunity, but the resulting Th2-biased response could be redirected to the 
Thl phenotype by IL-10 neutralization. Severe impairment of the macrophage and neutrophil 
response to infection was observed in IL-6-deficient mice, but administration of IL-6 would 
increase both neutrophil response and resistance to infection.  IL-6 seems to oppose the Th2- 
promoting role of IL-10 in candidiasis, its early regulatory activity involving effects on neutro- 
phil function. 
I 
'L-6 is  a  multifunctional  cytokine that  regulates various 
.aspects of the immune response, acute-phase reaction, and 
hematopoiesis  (1).  Although  not  produced  under  normal 
circumstances, IL-6 is abnormally produced in a number of 
inflammatory, immune,  and infectious diseases.  However, 
because of the pleiotropic activity of the cytokine and the 
complex interplay of different cytokines with similar activi- 
ties (2), the specific role of IL-6 in each pathological condi- 
tion  has  not  yet been  defined.  In human  infection  with 
HIV (3),  but also in several experimental infections,  high 
levels of IL-6 correlate with susceptibility to infection (4, 5) 
and severity of the associated disease (6). Yet, IL-6 neutral- 
ization has been found to be protective in most (7,  8) but 
not all  (9)  of these  experimental infections.  One  explana- 
tion may be the unexpected detection of high levels oflL-6 
in  anti-IL-6--treated mice,  indicating  the  possible  occur- 
rence  of "chaperoning"  effects  (7,  10).  For  this  reason, 
mice with a targeted mutation should provide a more use- 
ful means of evaluating the role of IL-6 in vivo. 
Candida  albicans  is  an  opportunistic  fungal  pathogen 
commonly found  in  the  gastrointestinal  (GI)  tract  of hu- 
mans  (11).  Dissemination,  which  occurs under conditions 
lAbbreviations used in  this paper: GI, gastrointestinal; NO,  nitric oxide; 
PCA-2, live vaccine strain of C. albicans; I~T, reverse  transcriptase. 
that compromise the host immune system (12),  results in a 
progressive disease associated with a high rate of mortality. 
In mice, the outcome of C.  albicans infection is largely de- 
pendent upon the type of predominant Th cell subset (13, 
14).  Thl  cell responses associated with protection occur in 
genetically resistant mice after mouse vaccination with live 
vaccine strains of the yeast. Thl responses are also detected 
in susceptible mice after neutralization of IL-4 (15) or IL-10 
(16).  These redirected responses lead to protection and on- 
set of lasting anticandidal resistance. In contrast, unopposed 
Th2 cell responses are associated with susceptibility to in- 
fection and  disease progression,  as observed in genetically 
susceptible mice (17)  and in resistant mice depleted of en- 
dogenous IFN-~ (18),  IL-12 (19),  or TGF-[3 (20). 
In the  course of candidal infections,  IL-6 is rapidly de- 
tected  in  sera  (21)  and  the  cytokine  is  also  produced  by 
CD4 + Th2 cells upon antigen-specific stimulation in vitro 
(15).  In addition,  overexpression of IL-6 in CAT/enhancer 
binding protein  [3-deficient mice has recently been found 
to  correlate with  development of yeast-specific Th2-type 
responses  (22).  Although pointing to a link between IL-6 
production and disease outcome, these results do not clarify 
the  functional  role  of IL-6 in  candidal  infections.  In this 
study,  IL-6-deficient  mice  generated  by  gene  targeting 
(23),  were used to assess the  role  of IL-6 in  resistance to 
Candida.  IL-6-deficient (IL-6-/-)  mice were found to be 
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susceptibility correlated with defective neutrophil function 
and the  development of a  T  cell reactivity biased towards 
the Th2 pathway. 
Materials and Methods 
Mice.  IL-6-/-  and +/+  female nfice were bred in our bar- 
rier facility, and were used by the age of 8-10 wk. The generation 
and genetic background of these mice have been described in de- 
tail (23).  Mice were  maintained in standard conditions under a 
12-h  light-dark  cycle,  and  provided  irradiated  food  (4RF21; 
Mucedola SILL; Settimo Milanese, Milan, Italy) and chlorinated 
water ad libitum. 129/SV/EV  mice  (24),  8-10 wk  old, were  a 
kind gift from E.  Robertson (Harvard Medical School, Boston, 
MA) live vaccine strain of C. albicans and were bred at Istituto di 
Ricerche  di  Biologia  Molecolare  P.  Angeletti.  Female  CD2F1 
mice  (H-2a/H-2a),  6-8  wk  old,  were  obtained  from  Charles 
River  (Calco,  Milan,  Italy).  Procedures  involving animals and 
their care were conducted in conformity with national and inter- 
national laws and policies. 
Yeasts, Infections, In Vivo Analysis and Treatments.  The origin and 
characteristics of the  C.  albicans highly virulent CA-6 strain and 
the live vaccine strain PCA-2 used in this study have already been 
described in detail (17).  For infection, cells were washed twice in 
saline, and diluted to  the desired density to be injected intrave- 
nously or intragastrically into mice. Quantification of yeast cells 
in organs of infected mice (four to six per group) was performed 
by a plate dilution method, using Sabouraud dextrose  agar,  and 
results (means  -+  SEM)  were  expressed  as  CFU per organ. For 
histology, tissues were excised and immediately fixed in formalin. 
Sections (3-4 p~m) of paraffin-embedded tissues were stained with 
periodic acid-Schiff reagent and examined for  histology,  as de- 
scribed (25).  Mice succumbing to yeast challenge were routinely 
necropsied for histopathological confirmation of disseminated can- 
didiasis.  For differential blood counts, animals were bled through 
the tail vein and smears were stained with May-Griinwald Giemsa 
reagents  (Sigma Chemical Co.,  St.  Louis, MO)  before  analysis. 
Recombinant human IL-6 was  produced  in Escherichia coli and 
purified to homogeneity according to published procedures, with 
minor modifications (26).  Protein concentration was determined 
by analysis of the purified product.  The specific bioactivity was 
2  ￿  10 s U/rag of protein as assessed by the 7TD1 cell growth as- 
say (27).  The recombinant IL-6 (10 /~g) was given in 0.2 ml s.c. 
ofPBS 4 h before and 1 d after challenge. Control mace received 
vehicle alone. IL-10-neutralizing antibodies (100  ~zg of affinity- 
purified mAb from SXC-1  hybridoma; American Type Culture 
Collection,  Rockville, MD)  was  injected into mice  1 d  before 
challenge. Depletion of neutrophils was performed by injecting 
the mice 4 h before infection with 30 p.g i.p. of the affinity-puri- 
fied RB6-8C5 rat IgG2b antibody, a gift from Dr. IL.L. Coffman 
(DNAX  Research  Institute,  Palo  Alto,  CA).  An  equivalent 
amount  of  isotype-matched  antibodies  (Zymed  Laboratories, 
Inc., South San Francisco, CA) was injected into control mice. 
Endotoxin  was  removed  from  all  solutions  with  Detoxi-gel 
(Pierce Chemical Co., Rockford, IL). 
Macrophage Cultures and Nitrite Determination.  Macrophages  were 
obtained from spleen cell suspensions and nitrite concentration, a 
measure of nitric oxide  (NO)  synthesis, was  determined as de- 
scribed (28).  Briefly, plastic adherent spleen cells were incubated 
overnight in the presence of 100 U/m] of rlFN-~/ and 10 ng/ml 
of LPS (Sigma Chemical Co.). Viable yeast cells were then added, 
and supernatants were removed after 4 h  and assessed for nitrite 
content. 
Antibody Assay.  A micro-ELISA procedure was employed to 
quantitate total and yeast-specific antibodies in sera  (IgG2a and 
lgE) and fecal samples (IgA) of mice (17, 25). 
Cell Cultures.  Unfractionated splenocytes (5  ￿  106/ml) were 
cultured  in  the  presence  of 5  ￿  105  heat-inactivated  Candida 
cells, in RPMI  1640 medium, 10%  FCS, and antibiotics. CD4 + 
lymphocytes were positively selected from pools of spleen cells by 
means of a  panning procedure  using purified antimurine CD4 
mAb  GK1.5,  which  resulted  in  a  >95%  pure  population  via 
FACS  |  analysis. CD4 + (5  ￿  106) cells were cultured in the pres- 
ence of 5  ￿  10  s irradiated (2,000 rad) splenocytes and heat-inac- 
tivated yeast cells. Cytokine measurements were performed in su- 
pernatants collected after 48 h, as described (17). 
Enumeration  of Cytokine-producing  CD4 § Cells and  Cytokine As- 
says.  The procedure used to enumerate cytokine-producing cells 
was based on a spot ELISA, using CD4 §  cells  from freshly iso- 
lated  splenocytes,  as  described previously (16,  25).  Source  and 
characteristics of the antibody reagents used in IFN-y, IL-2, IL-4, 
and IL-10 ELISPOT and ELISA assays were as described (16,  19, 
29).  In IL-6 measurement, two-site ELISA involved the use of 
mAb MP5-20F3  in combination with biotinylated monoclonal 
MP5-32cll  (PharMingen, San Diego, CA). In the ELISPOT as- 
says, spots were counted with the aid of a dissecting microscope, 
and results were expressed as the mean number of cytokine-pro- 
ducing cells per 104 cells, calculated using replicates of serial two- 
fold dilutions of cells pooled from four mice per group. Cytokine 
titers were calculated by reference to standard curves constructed 
with known amounts of the recombinant cytokines. 
RNA Preparation and Reverse Transcriptase.  CD4 +  lymphocytes 
(2  ￿  107 cells) or adherent macrophages from pooled spleens of 
three to four animals were subjected to RNA extraction by the 
guanidium thiocyanate-phenol-chloroform procedure, as described 
(30).  Briefly, 3  Izg of total RNA was incubated with 0.5 p,g of 
oligo(dT)  (Pharmacia, Uppsala,  Sweden) for 3 rain at 65~  and 
chilled on ice for 5 rain. Each sample was then incubated for 2 h 
at 42~  after adding 20 U  RNase inhibitors (Boehringer Mann- 
heim, Milan, Italy),  1.5 mM deoxynucleoside triphosphates, 25 U 
avian myeloblastosis virus reverse transcriptase (RT; Boehringer 
Mannheim), and RT buffer (50 mM Tris-HC1, pH  8.3,  8  mM 
MgC12,  30  mM  KCI,  and  10  m/Vl dithiothreitol,  final concen- 
tration) in a final volume of 20 ~1. cDNA was diluted to a total 
volume  of 500  ILl  with  TE  buffer  (10  mM  Tris-HC1,  1  mM 
EDTA, pH 8.0)  and frozen at -20~  until use. Amplification of 
synthesized cDNA from each sample was carried out as described 
previously (31).  Briefly, 5  I*1 of cDNA was added to a reaction 
mixture containing 50 mlVl KC1,  10 mM Tris-HC1, pH 8.3, 3.0 
mM MgC1  z, 0.01% gelatin, 0.2  deoxynucleoside triphosphate, 
1 I~M of each primer, and 2.5 U  AmpliTaq polymerase (Perkin- 
Elmer Corp.,  Hayward,  CA).  Each  100-1xl sample was  overlaid 
with 75  p~l mineral oil (Sigma Chemical Co.) and incubated in a 
DNA Thermal Cycler 480 (Perk.in-Elmer Corp.) for a total of 30 
cycles for each cytokine. For [3-actin-specific primers, each cycle 
consisted of 1 rain at 94~  1 man at 60~  and I  man at 72~  for 
IL-4, 1 rain at 94~  1 n-fin at 67~  and 1 rain at 72~  for IL-10, 
10 s at 91~  25 s at 59~  and 25 s at 72~  and for IL-12p40, I rain 
at 94~  1 rain at 67~  and 1 rain at 72~  IL-4, IL-10, and IL- 
12p40 primers and the positive controls were  as described else- 
where (15,  16, 19, 29). The [3-actin primers were used as a control 
for both RT and the PCR reaction itself,  and also for comparing 
the  amount of products  from  samples  obtained with  the  same 
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electrophoresis  and  visualized  by  ethidium  bromide  staining. 
PCP,-assisted mRNA amplification was repeated at least twice for 
at least  two separately prepared cDNA samples for each experi- 
ment.  Data are representative  of at least  three  different  experi- 
ments. 
Statistical Analysis.  Statistical  analysis was done using the Stu- 
dent's t test; P <0.05 was considered significant. 
Results 
IL-6- /-  Are More Susceptible  than IL-6+ /+  Mice to  C. 
albicans Infections.  To evaluate the susceptibility of IL-6-/- 
and IL-6+/+  mice to  C.  albicans infection,  mice were in- 
jected intravenously with different doses (10 6 or  10 5  )  either 
of highly  virulent  CA-6  yeast cells  or  of the  live  vaccine 
strain PCA-2.  Groups of mice were instead infected intra- 
gastrically with  108  CA-6  cells.  The  animals  were  moni- 
tored for mortality, fungal load in the organs, and resistance 
to secondary challenge. Although the median survival times 
of mice injected intravenously with the higher CA-6 inoc- 
ulum did not differ between the two types of infected host, 
IL-6-deficient mice succumbed to infection with  105 cells, 
in  contrast  to  the  long-term  survival  of IL-6+/+  mice 
(Table  1).  However,  both  IL-6+/+  and  -/-  mice  re- 
sisted  challenge  with  104  CA-6  cells  (data  not  shown). 
IL-6-/-  mice  were  also  more  susceptible  to  the  higher 
(10 6  cells)  inocnlum  of PCA-2,  with  a  greater  than  65% 
death  rate within  3  wk of infection.  With  the  lower  (105 
cells) inoculum,  both types of mice survived primary chal- 
lenge;  however,  they exhibited  disparate  susceptibilities  to 
rechallenge with virulent CA-6, in that only the IL-6+/+ 
mice resisted the secondary infection (Table 1). 
As the genetic background has been found to contribute 
to  the  resistance  of an  IL-4-deficient  129  mouse  strain  to 
murine acquired immunodeficiency syndrome (MAIDS) in- 
Table 1.  Susceptibility of lL-6-/-  and IL-6 + / + Mice to 
C. albicans infection 
Infection  IL-6 -/-  IL-6 +/+ 
Yeast  Dose  R.oute  MST  D/T  MST  D/T 
d 
CA-6  10  6  i.v.  5  8/8*  8  8/8 
10  s  i.v.  8  8/8  >60  0/8 
PCA-2  106  i.v.  18  6/8  >60  0/8 
10 s  i.v.  >60  0/8*  >60  0/8* 
CA-6  108  i.g.  >60  0/6  >60  0/8 
*Dead mice over total mice injected. The MST of control 129/SV/EV 
mice injected intravenously with  106 or 10  s CA-6 cells were  14 and 
>60 d, respectively. 
*When parallel groups oflL-6-/-  and +/+ mice surviving infection 
with 10  s PCA-2 cells were rechallenged with CA-6 (10 6 cells, 2 wk af- 
ter primary infection), only the former animals succumbed to virulent 
challenge with an MST of 3 d. 
i.g., intragastric; MIST, median survival time. 
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fection  (32), we assessed the relative susceptibility to CA-6 
infection  of 129/SV/EV  mice  (24),  the  strain from which 
the  embryonic stem cells  (CCE)  used for homologous  re- 
combination  had been  derived  (23).  The  results  (see note 
to Table 1) showed these mice to be as resistant to infection 
as  the  IL-6+/+  mice,  thus  ruling  out  that  genetic  back- 
ground, rather than IL-6 defciency, might be primarily re- 
sponsible for the susceptibility of IL-6-/-  mice to C. albi- 
cans infection. 
Quantification  of yeast cells recovered from the systemi- 
cally infected  mice  revealed  the  presence  of higher  num- 
bers of C.  albicans viable units in the kidneys, livers and, in 
particular, brains, of IL-6-/-  mice (Fig.  1 A). 
Based  on  the  finding  that  IL-6 promotes  IgA secretion 
by Peyer's patches  (33)  and that IL-6-/-  mice fail to de- 
velop strong mucosal antibody responses to viral infection 
(34), we examined the course ofGI candidiasis in IL-6-/- 
and  IL-6+/+  mice.  Course  and  outcome  of GI infection 
are influenced by the host mucosal immune status (25). No 
differences  in  survival  could  be  found  after  intragastric 
challenge  (Table  1).  However,  analogous  to  what  was 
found  in the  systemic infection,  the  number  of yeast cells 
recovered from the stomachs of IL-6-/-  mice was higher 
than that observed in IL-6+/+  mice, at all time points ex- 
amined  (Fig.  1  B),  even though  both types of host would 
eventually clear their mucosal infections.  It is interesting to 
note that extensive fungal growth was detected in the esoph- 
agus  of IL-6-/-  mice,  an  occurrence  typical of severely 
immunodeficient  animals  (35).  Also,  increased  yeast  dis- 
semination occurred to the kidneys in IL-6-/-  mice. 
Histological  examination  of the  kidneys  from mice  in- 
fected intravenously with CA-6  cells  (Fig.  2, A  and B) re- 
vealed the presence ofmicroabscesses with abundant neutro- 
phil infiltration within tubules, particularly in IL-6-/-  mice. 
In addition,  lesions  tended  to be larger,  showed  consider- 
able necrosis, and contained hyphal aggregates and yeast cells 
in IL-6-/-  mice, whereas signs of progressive resolution 
with no visible yeasts were observed in the wild-type con- 
trols. Of interest, inflammatory lesions in the kidney cortex 
were almost exclusively found in the  IL-6+/+  mice (Fig. 
2, A  and B), raising the possibility that IL-6 might have an 
ambivalent role in the pathogenesis of renal candidiasis, as it 
is required for development of cortex lesions. 
In  the  GI infection  (Fig.  2,  C  and  D),  sections  of the 
stomachs from either type of mice revealed the presence of 
abscesses in the region of the cardiac-atrial fold, the princi- 
pal site of gastric infection in mice (36). Abscesses, charac- 
terized  by  yeast  cells  surrounded  by  a  keratinized  upper 
layer and a basal epithelium layer, were more numerous in 
IL-6-/-  than  +/+  mice.  Also,  extensive  mononuclear 
cell and  neutrophil  responses were  evident in  the  submu- 
cosa and the lamina propria of only IL-6-/-  mice. 
All together,  these results indicated  that IL-6 deficiency 
in mice is associated with increased susceptibility and more 
severe pathology  caused by systemic  and  mucosal  C.  albi- 
cans infections. 
Susceptibility  of lL-6-/-  Mice to  Candidiasis  Is Associated 
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Figure 1.  Fungal  growth in the organs oflL-6-/- 
and IL-6+/+ mice. Enumeration of yeast cells recov- 
ered from different organs of IL-6-/- and +/+ mice 
at 1 wk after i.v. injection of 10  s (I~) or 104 ([]) viru- 
lent CA-6 cells (A) or at 2, 4, and 8 wk after intragas- 
tric challenge with 108 CA-6 cells (B). Cumulative data 
from two  experiments (mean +  SE,  six animals per 
group). (Vertical bars) Upper limit of the standard error. 
(') No viable yeast units found. 
protective forms of specific immunity to C.  albicans corre- 
late in mice with the respective expansion of Thl  and Th2 
cells (13), parameters of CD4 + Th cell immunity were ex- 
amined in IL-6-/-  and control mice with systemic or GI 
candidiasis. Ig levels as well as patterns ofThl/Th2  cytokine 
production were  evaluated in mice injected  intravenously 
with CA-6 or PCA-2 ceils, or infected intragastrically with 
CA-6 cells.  In uninfected mice, no differences were found 
in the  production  of IgG2a or IgE, although  a  significant 
decrease in total IgA fecal content was present in IL-6-/- 
mice  (Fig.  3).  However,  after  i.v.  infection with PCA-2, 
Candida-specific  IgE levels were higher in IL-6+/+  mice, 
whereas  in  contrast,  specific  IgG2a levels  were  higher  in 
IL-6-/-  mice.  In GI-infected mice,  the  Candida-specific 
IgA content  was significandy lower in  fecal samples  from 
IL-6-/-  mice (Fig. 3). 
For studying cytokine production,  we assessed cytokine 
levels in sera and frequencies of cytokine-producing cells in 
spleens,  together with the qualitative pattern ofcytokine gene 
expression.  Because circulating levels of IL-12, rather than 
IFN-',/,  correlate  with  Thl  development  in  candidiasis 
(29), we quantitated  the presence ofbioactive IL-12 in the 
sera  of IL-6-/-  and  control mice infected with  PCA-2. 
We  found  (Fig.  3)  these  levels  to  be  higher  in  resistant 
IL-6+/+  than  in  susceptible  IL-6-/-  mice,  although 
IL-12 could be  detected  in both  cases.  In contrast,  IL-12 
levels were below the detection limits of the assay in both 
types of uninfected host. Fig. 3 also shows that, whereas se- 
rum levels of IL-4 did not apparently increase  in response 
to infection in either type of mice,  the levels of circulating 
IL-10,  although  increased  in  both  types  of mice,  were 
higher in IL-6-/-  mice with systemic or GI infection. 
Depending on the yeast/host combination and outcome 
of infection,  IL-4 (15,  37),  IL-10 (16),  and IL-12 (19,  29) 
are  key contributors  to the  cytokine balance  affecting Th 
cell  differentiation.  Therefore,  we  evaluated  the  simulta- 
neous  expression  of  these  cytokines  in  the  spleens  of 
IL-6-/-  and  control  mice  injected  intravenously  with 
CA-6 or PCA-2 cells.  6 d after infection, spleens were har- 
vested  and  message  levels  of IL-4,  IL-10,  and  IL-12p40 
were  assayed  in  purified  CD4 +  cells  or  macrophages  by 
RT-PCR  analysis.  The  results  (Fig.  4)  showed  that  the 
IL-4--specific message  was  not  (PCA-2)  or barely  (CA-6) 
detectable in CD4 +  cells  from Candida-infected  IL-6-/- 
mice but was clearly expressed by IL-6+/+  and 129 mice. 
In contrast,  IL-10 messages were present in IL-6-/-  and 
+/+  mice,  as  well  as  in  129  mice.  Moreover,  the 
IL-12p40 message was present in all types of mice injected 
with PCA-2 but not with CA-6. 
To correlate these findings with cytokine production by 
CD4 +  cells from infected mice,  the  frequencies  of CD4 + 
cells  producing  IFN-y,  IL-2,  IL-4,  and  IL-10  cytokines 
were determined in IL-6-/-  and +/+  mice after primary 
PCA-2  infection  or after  reinfection  at  2  wk  with  CA-6 
cells. At 3 d after primary or secondary infection, the num- 
ber of IFN-~/-, IL-2-, IL-4--, and IL-10-producing CD4 + 
cells  (freshly isolated from the spleens of infected mice) was 
determined  by  means  of an  ELISPOT  assay  (Fig.  5).  A 
fourfold increase  in the  number  of IL-10-producing cells 
and  an  almost  twofold increase  for those  producing  IL-4 
were found in the  spleens  of IL-6-/-  mice after PCA-2 
infection as compared to uninfected mice.  In contrast,  the 
frequencies of cytokine-producing cells in infected IL-6 +/+ 
mice  were  not significantly different  from those  in  unin- 
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with candidiasis.  (A and  B)  Periodic acid-Schiff~tained sections  from kidneys  of 
IL-6-/-  (A) or IL-6+/+ (B) mice at 5 d after infection with virulent C. albicans. In 
IL-6-/-  mice, an inflammatory  lesion  (arrows) is present  with large necrotic  areas 
and hyphal cells. (C, D) Medial sections from the stomach of IL-6+/+  (C) and IL- 
6-/-  (D) mice inoculated  intragastrically with C. albicans 2 wk earlier. In IL-6-/- 
mice, note the presence  of multiple,  eruptive  abscesses on the mucosal surface, and 
acanthosis, parakeratosis, and abundant  inflammatory cells in the submucosa and lam- 
ina  propria.  The  numbers  of abscesses (arrows) and  hyphal  cells were  appreciably 
lower in IL-6+/+ mice. Bars: (A and B) 400 p,m; (inset  A and B) 50 p,m; (C and/3) 
100 p,m. 
fected  controls.  After  reinfection,  a  significant  increase  in 
the  number  of IL-4-producing  cells  was  observed  in  the 
IL-6-deficient mice, yet the numbers  oflFN-~/-  and IL-2- 
producing  cells  did  not  increase,  as  opposed  to  what  was 
observed in IL-6+/+  mice. 
Taken together,  these results indicated  that susceptibility 
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of IL-6-/-  mice  to  candidiasis  might be  associated  with 
the  activation of CD4 +  Th2  cells and  a  preponderant  pro- 
duction of IL-10. 
IL- 10  Neutralization  Enhances  Th 1~  Resistance  of 
IL-6-/-  Mice to Candidiasis.  As  IL-10  impairs  develop- 
ment of protective anticandidal Thl  responses by inhibiting <  <0.5  * * 
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~<25  10 
<7  <2 
--  PCA-2  --  PCA-2  CA-6  --  PCA-2  CA-6 
iv  iv  iv  ig  iv  iv  ig 
Yeast 
Route 
Figure 3,  lg production and serum cytokine levels  in C. albicans-infected IL-6-/- and IL-6+/+ mice. Mice were injected intravenously  with 105 
CA-6 or 106 PCA-2 cells or intragastrically  with 108 CA-6 cells. Cytokines  and Candida-specific IgG2a and IgE in serum and IgA in fecal samples were 
assessed 6 d after infection. (  ) Uninfected  control mice; ([3) IL-6-/- mice; and (m) IL-6+/+ mice. (Insets) Levels of total Ig production by unin- 
fected mice. (*) Below the detection limit of the assay, as indicated  on the y-axis. 
early macrophage production of NO  (16)  and IL-12 (29), 
we assessed  such productions together with the pattern of 
resistance in IL-6-/-  and control mice after intravenous 
challenge with PCA-2 in the presence of IL-10--neutraliz- 
ing mAb (Table 2). IL-10 neutralization did not affect resis- 
tance in IL-6 +/+  mice, yet significantly increased survival 
in IL-6-/-  mice. The protective effect ofanti-IL-10 was 
associated with elevated serum levels ofbioactive IL-12 and 
upregulation of NO release by activated macrophages; both 
functions were defective in IL-6-/-  nfice, infected (Table 
2) or not (data not shown) with PCA-2. 
Therefore,  overproduction of IL-10 seemed to  play an 
important role in the susceptibility to Candida infection and 
the  development  of  nonhealing  Th2  cell  responses  in 
IL-6-/-  mice. However, the T  cell response could be re- 
directed to a Thl pattern of reactivity by anti-IL-10 treat- 
ment. 
Susceptibility  and Resistance to  Candidiasis  Correlate with the 
Levels of Endogenous IL-6 in  Conventional Mice.  To  further 
define the  role  of IL-6  in candidiasis, we  measured  IL-6 
production in previously established models of healing or 
nonhealing infections in which the patterns of Th cell re- 
sponses have been best characterized (19). Accordingly, IL-6 
levels were measured in culture supernatants of splenocytes 
from CD2Fi  mice, injected intravenously 2  d  earlier with 
escalating doses  of either CA-6  (nonhealing infection) or 
PCA-2 (healing infection) after restimulation in vitro with 
Candida  antigens (Fig.  6).  In both infections, the produc- 
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Figure  4.  Analysis  of cytokine gene expression in 
IL-6-/-, IL-6+/+, and 129 mice with systemic can- 
didiasis. Mice were injected intravenously with  1(~ 
CA-6 or 106 PCA-2 cells, 6 d before spleen harvesting 
for purification  ofCD4 + T cells and macrophages. IL-4 
and IL-10 (in CD4  + T cells) and IL-12p40 (in mac- 
rophages) gene expression was assessed by RT-PCR. 
(N) No DNA added to the amplification  mix during 
PCR;  (C) [3-actin- or cytokine~pecific controls; and 
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Figure 5.  Frequencies  ofcytokine-producing cells  in IL-6-/- 
and IL-6 +/+ mice with candidiasis.  The number of cytokine- 
producing CD4  + cells was determined in IL-6-/-  ([7]) or 
IL-6+/+ (I) noninfected  mice (a), at 3 d after challenge with 
106 PCA-2 cells (b), or with 106 CA-6 cells 14 d after PCA-2 
(c). Values are the means +  SE of four replicates obtained with 
pooled cells from four mice per group. (*) Significantly differ- 
ent from IL-6+/+ mice. 
tion of IL-6  directly correlated with the  fungal dose  used 
for the in vivo challenge, being the highest in mice given 
the largest inoculum of the yeast. A  similar dependence of 
IL-6  production  on  size  of microbial challenge  has  been 
observed  in  Listeria  (38)  and  HIV  (39)  infections.  In  our 
experiments  with  CD2F 1 mice  challenged  with  high-  or 
low-virulence Candida,  the highest production of IL-6 was 
detected in nonhealer mice (Fig. 6) and relatively high lev- 
els of IL-6 were also found in early sera from these animals 
(data not shown),  analogous to the results of others in an- 
other system  (21).  However,  in experiments not reported 
Table 2.  IL- 10 Neutralization Increases Th 1-mediated Resistance 
in IL-6-/-  Mice with Systemic Candidiasis 
Anti-IL-10 
Mice  mAb*  MST  D/T  NO T  IL-12p70 
d 
IL-6 --/-*  -:~  14  6/6  9.4~  984 •  4411 
IL-6 -/-  +  >60  2/6  18￿82  1,850 +-- 141 
IL-6 +/+  -  >60  0/6  14  2,180 •  194 
IL-6 +/+  +  >60  0/6  16  2,240 •  155 
*  Mice were injected intravenously  with 106 PCA-2 cells. 
*Anti-IL10--neutralizing  mAb (100 p.g/mouse)  was given intraperito- 
neally 4 h before challenge. Control mice received an equal amount of 
isotype-matched purified antibodies. 
~Adherent macrophages  from 3-d-infected mice were cultured over- 
night with IFN-~/ (100 U/ml) and LPS (10 ng/rul) before determina- 
tion of nitrite content (Ixm/107 cells). 
IIIL-12p70 (ng/ml) was determined in sera pooled from three to five 
mice at 6 d of infection. 
￿82 <0.05 (anti-IL-10-treated versus controls). 
here,  we  found that  administration of IL-6 to healer mice 
(with an apparently low endogenous production of the cy- 
tokine)  decreased fungal load,  which would instead be in- 
creased  by IL-6  neutralization in nonhealer mice.  There- 
fore,  the  early  production  of  IL-6  may  represent  an 
important  defense  mechanism to  limit candidal infection. 
Because IL-6 does not affect the growth of Candida  in vitro 
(our unpublished observations), it is likely that the effects of 
IL-6  in  vivo  occur  via  activation  of  antifungal  effector 
functions, such as those typically mediated by phagocytic cells. 
400- 
300. 
..-,  200. 
100 
<5, 
0  0.5  5  50 
0.1  1  10 
(xl03 CA-6) 
(xlO  6 PCA-2) 
Number of C. albicans cells 
Figure 6.  IL-6 production in mice with candidiasis. CD2F~ mice were 
injected  with escalating doses of CA-6 (Q'O)  or PCA-2 (O~)  cells. 
Splenocytes from 2-d-infected mice were stimulated in vitro with Can- 
dida antigen before IL-6 determination in culture supematants by ELISA. 
IL-6 production by splenocytes from noninfected mice was below the de- 
tection hmit of the assay (<5 U/ml). Values are the means +  SE of two 
independent experiments. 
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creases Resistance in IL-6-deficient Mice.  One  such  effector 
function is mediated by neutrophils, such that their ablation 
in  vivo  increases  susceptibility to  candidal  infection  and 
promotes Th2  development (13).  Significandy, 1L-6--defi- 
cient mice  are  unable  to  mount  peripheral blood neutro- 
philia in  response  to  Listeria  infection  (40).  Therefore,  it 
seemed  of interest  to  measure  the  number  of peripheral 
blood neutrophils in IL-6-/-  and  +/+  mice before and 
after C. albicans infection. Neutrophil counts did not signif- 
icantly differ in uninfected IL-6-deficient and control mice 
(Table 3,  groups  1 and 6);  however,  at 2  d  after infection, 
the  number  of peripheral blood  neutrophils  failed to  in- 
crease in  IL-6-/-  mice  in  contrast to  what  observed in 
IL-6 + / +  mice (groups 2 and 7). 
To  define the role of neutrophils as antifungal effectors 
in IL-6-/-  and  +/+  mice, both types of mice were de- 
pleted ofneutrophils by treatment with grannlocyte-deplet- 
ing mAb,  according to  a  procedure  estabhshed previously 
in yeast-infected CD2F1  mice  (13).  Neutrophil depletion, 
at the time of C.  albicans challenge, dramatically increased 
susceptibility to infection in both types of mice, as shown 
by the occurrence of median survival times of 2 d  (Table 3, 
groups 3  and  8).  However,  recombinant human  IL-6 ad- 
ministered to yeast-infected IL-6-/-  mice  (group 4),  re- 
sulted in  a  dramatic increase in  the  number  of peripheral 
blood neutrophils, provided that the animals had not been 
treated with the mAb (group 5). Concomitantly, there was 
a  twofold decrease in the number  of yeast cells recovered 
from  the  kidneys  (groups  2  and  4).  The  number  of yeast 
units in the kidneys was also lower at 7 d of infection (four- 
fold decrease, data not shown). It is interesting to note that 
no  such  effect was  observed in neutrophil-depleted mice. 
Indeed, similar to the effect of IL-10 neutralization (Table 
2), the administration ofrlL-6 to the yeast-infected IL-6-/- 
mice significantly increased their survival times, from  14 to 
>60 d  (groups 2 and 4, respectively, Table 3). 
Discussion 
This  study demonstrates  that  IL-6  deficiency,  resulting 
from gene targeting, increases mouse susceptibility to C. al- 
bicans  infection  and  prevents  development  of protective 
Thl-mediated immunity. This effect is reversed by neutral- 
ization  of endogenous  IL-10  or  administration  of rlL-6, 
suggesting that production oflL-6 may represent an impor- 
tant  defense  mechanism  against  candidal  infection.  How- 
ever,  the  limited  IL-6 production  found  in  conventional 
mice with healing infection of the yeast would suggest that 
the production of IL-6 must be stricdy regulated, in accor- 
dance  with  the  notion  that  immunopathological  conse- 
quences may result from its deregulation (41).  This is also 
consistent with previous findings of a  deleterious effect of 
IL-6 overexpression in C/EBPI3  mice infected with  Can- 
dida (22). The increase in fungal load found not only in the 
kidneys and livers, but also in the brains of systemically in- 
fected IL-6-deficient mice may indicate a  possible unique 
role for  IL-6 in  immunosurveiUance  in  this  compartment 
(42).  However,  another observation in this study was  that 
highly susceptible IL-6-deficient mice  did not  develop as 
severe renal pathology in the cortex as the otherwise resis- 
tant IL-6+/+  mice. Because of the known involvement of 
IL-6 in mesangial prohferative disorders (43),  it is possible 
that this cytokine plays a deleterious role in renal disease by 
Candida. 
The interplay between the innate and acquired immune 
Table 3.  IL-6 Administration  Induces Peripheral Blood Neutrophilia and Increases Resistance in C. albicans-infected IL-6-/-  Mice 
Treatment* 
Antigranulocyte  Recombinant  Neutrophils/mm  3  CFU 
Group  Mice  mAb  human IL-6  (--- SE)  (X 10 3)  MST  D/T 
d 
1  IL-6-/ ....  980 •  120~  -II  -  - 
2  IL-6-/-  -  -  1020  •  165  150  •  10  14  6/6 
3  IL-6-/-  +  -  21  •  8  ND  2  10/10 
4  IL-6-/-  -  +  2340 •  204  78 •  8  >60  1/6 
5  IL-6-/-  +  +  38 •  11  ND  2  10/10 
6  IL-6+/+  -  -  1521 ~  280  -  -  - 
7  IL-6+/+  -  --  2780  •  220  124  •  27  >60  0/6 
8  IL-6+/+  +  -  52 •  18  ND  2  10/10 
*Mice were injected intravenously with 106 PCA-2 cells, with the exception of groups 1 and 6. 
*Antigranulocyte mAb (30 ~g i.p. of affinity-purified RB6-8C5 mAb) was given 4 h before infection. A total of 30 Ixg/mouse of recombinant hu- 
man IL-6 was given subcutaneously 4 h before and 1 d after infection. 
~Absolute numbers of peripheral blood neutrophils as determined by tail bleeds at 2 d after infection. 
PJCFUs (mean +  SE) were determined in kidneys 2 d after infection. The difference between groups 2 and 4 is statistically  significant (P <0.05). 
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fense against  infections (44), and IL-6, through either en- 
docrine, paracrine, or autocrine pathways of activation, ap- 
pears  to  be  important  to  the  successful  development  of 
both forms of  immunity. However, IL-6 may be more crit- 
ical  in  the  promotion of cellular immunity  (45)  than  in 
short-term events, such as shock (46) and LPS-induced sys- 
temic inflammation (47).  IL-6 acts  as a potent costimula- 
tory signal  in CD4 + T  cell activation and promotes both 
cytotoxic T  cell differentiation and NK function (41).  A 
deficient IL-6 production is known to impair T  cell activa- 
tion and to increase susceptibility to Listeria infection (45). 
IL-6 is also required for the induction of T  cell-mediated 
resistance to Mycobacterium avium  (48). 
We  have  observed that  IL-6-/-  mice  default to  the 
Th2  pathway  in  response  to  a  low-virulence  C.  albicans 
strain that, in contrast, induces a preponderance of Thl re- 
sponses in IL-6+/+ mice. IL-10, rather than IL-4, was the 
main cytokine produced by the IL-6-/-  former mice in 
response to primary infection. This could explain the pat- 
tern of Ig production observed in sera as well as the low 
levels of bioactive IL-12p70  produced by the  IL-6-defi- 
cient mice. IL-10 induces the synthesis of IgG with no di- 
rect  effect on  IgE  production  (49)  and  strongly  inhibits 
IL-12 production (50). However, the number oflL-4-pro- 
ducing CD4 + cells was greatly increased by yeast reinfec- 
tion, which indicates that memory CD4 + T  cells will pro- 
duce substantial  amounts of IL-4 upon secondary challenge. 
The finding of a relatively low production of IL-4 in IL- 
6+/+  and 129 mice challenged with virulent Candida sug- 
gests that genetically determined factors in addition to IL-4 
could mediate susceptibility to  infection in these mice,  a 
possibility that may be at work in MAIDS infection as well 
(32).  The genetic T  cell background is likewise important 
in determining default Th phenotype development in an in 
vitro system (51). 
Whether  IL-6  has  a  direct  effect  on  the  developing 
CD4 + T  cells in candidiasis  is unclear. We do not favor the 
hypothesis of a direct role, also considering the recent find- 
ing that the protective effect of rlL-6 in murine listeriosis  is 
independent of lymphocytes (40).  The low levels of IL-12 
produced by IL-6-deficient mice  may well  explain  their 
failure to mount a sufficient Thl  response. As a matter of 
fact, the finding of upregulated IL-12 production and in- 
creased  resistance  to  infection  after  IL-10  neutralization 
suggests  that  an  appropriate  immune  response  will  take 
place in IL-6-/-  mice when the effects of the opposing 
cytokine, IL-10, are neutralized. 
That IL-10 may prevent development of protective Thl 
responses in mice with candidiasis  has already been shown 
(52).  In addition,  in genetically susceptible DBA/2  mice, 
the emergence of  protective Thl reactivity after IL-10 neu- 
tralization is concomitant with upregulation of NO release 
by splenic macrophages  (16).  We have assessed NO  pro- 
duction by macrophages from IL-6-/-  and  +/+  mice 
infected with C.  albicans. Although NO release by elicited 
peritoneal (45)  or splenic macrophages in Listeria infection 
(40)  is  not  different in  independently  derived  IL-6-/- 
and control mice, we did observe defective NO  produc- 
tion  by  activated  splenic  macrophages  from  C.  albicans- 
infected IL-6-deficient mice. Because IL-10 neutralization 
was followed by upregulation of NO production, it is likely 
that IL-10 was primarily responsible for the impaired NO 
release observed in IL-6-/-  mice. Whether the (relative) 
overproduction of IL-10 is  directly related to  IL-6  defi- 
ciency remains to be clarified. 
It is interesting to note that increased production oflL-10 
is  a  common finding in  C.  albicans-infected  neutropenic 
mice (P,  omani L., A. Meucacci, E. Cenci, P,.. Spaccapelo, 
P. Puccetti, and F. Bistoni, manuscript in preparation). Af- 
ter neutrophil depletion,  otherwise resistant  mice  exhibit 
high susceptibility to infection associated with Th2, rather 
than Thl responses. Neutrophils may actively participate in 
the selection of the Th response by modifying the cytokine 
milieu at the time of infection, this being individually the 
most critical factor in Th cell differentiation to Candida (13). 
We  found that  the  number  of neutrophils was  lower in 
IL-6-/-  than in IL-6+/+  mice, and, in particular,  that 
IL-6-/-  mice  were  unable  to  mount  peripheral  blood 
neutrophilia in response to infection. A  similar condition 
has  recently been observed in  IL-6-deficient mice in re- 
sponse to Listeria infection (40).  However, an anticandidal 
effect was found to result from administration of exogenous 
IL-6;  this  correlated with  increased  counts  of circulating 
neutrophils.  The  therapeutic  activity of IL-6 was  lost in 
neutrophil-depleted mice, which suggests  a neutrophil de- 
pendence of the effect. These findings are in line with the 
IL-6--promoting activity on granulocyte and  macrophage 
colony development from murine progenitor cells (53) and 
with the significant increase in neutrophils observed after 
IL-6 injection (54). These data also suggest that IL-6 partic- 
ipates in the early defense to C. albicans infection by stimu- 
lating  neutrophils,  either  directly  or  indirectly.  IL-6  is 
known to influence the oxidative burst and destructive ca- 
pacity of human neutrophils (55), raising the possibility that 
the neutrophil effector function may be impaired in IL-6- 
deficient mice as well. 
All together, these results indicate that a defective innate 
immune  response,  such as  an inefficient neutrophil func- 
tion, together with the negative effect of unopposed cyto- 
kines, such as IL-10, on macrophage activity, may contrib- 
ute  to  the  inability  of  IL-6-deficient  mice  to  mount 
protective Thl  responses in candidiasis.  In GI infection, a 
further negative effect could result from impaired IgA se- 
cretion,  even though  the  precise role  of IgA in  mucosal 
candidiasis  is still to be defined (25). 
Thl development in candidiasis  appears to require a crit- 
ical balance  of cytokines acting  directly or indirectly on 
CD4 +  subset  differentiation. In  addition  to previous evi- 
dence for an obligatory role oflFN-y (18), IL-12 (19), and 
TGF-[3 (20), the present data establish IL-6 as another cyto- 
kine that, presumably via effects on innate response mecha- 
nisms, permits optimal development of Thl reactivity lead- 
ing to lasting anticandidal protection. 
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